Valerio Izzi, Juho Lakkala, Raman Devarajan, Eeva-Riitta Savolainen, Pirjo Koistinen, Ritva Heljasvaara, Taina Pihjajaniemi, Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia, Leukemia Research Reports, Volume 9, 2018, Pages 9-13, ISSN 2213-0489, https://doi.org/10.1016/j.lrr.2017.12.001
Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia
|Author:||Valerio Izzi1; Lakkala, Juho1; Devarajan, Raman1;|
1Centre of Excellence in Cell-Extracellular Matrix Research and Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland
2Nordlab Oulu and Institute of Diagnostics, Department of Clinical Chemistry, Oulu University Hospital, University of Oulu, Oulu, Finland
3Medical Research Center Oulu, Institute of Clinical Medicine, Oulu University Hospital, University of Oulu, Oulu, Finland
4Centre for Cancer Biomarkers (CCBIO), Department of Biomedicine, University of Bergen, N-5009 Bergen, Norway
|Online Access:||PDF Full Text (PDF, 0.5 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe201901111991
|Publish Date:|| 2019-01-11
Relapse of acute myeloid leukemia (AML) is still dramatically frequent, imposing the need for early markers to quantify such risk. Recent evidence point to a prominent role for extracellular matrix (ECM) in AML, but its prognostic value has not yet been investigated. Here we have investigated whether the expression of a 15-ECM gene signature could be applied to clinical AML research evaluating a retrospective cohort of 61 AML patients and 12 healthy donors. Results show that patients whose ECM signature expression is at least twice as that of healthy donors have considerably longer relapse-free survival, with further stage-specific therapy outcomes.
Leukemia research reports
|Pages:||9 - 13|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This work was supported by the Centre of Excellence Grant 2012–2017 of the Academy of Finland (284605), the Sigrid Jusélius Foundation, the Finnish Cancer Foundation; and the University of Oulu Graduate School.
|Academy of Finland Grant Number:||
284605 (Academy of Finland Funding decision)
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).